Technical Analysis for 0RQE - Idorsia Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 8.39% | |
| Oversold Stochastic | Weakness | 8.39% | |
| MACD Bearish Centerline Cross | Bearish | -0.39% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.39% | |
| Narrow Range Bar | Range Contraction | -0.39% |
Free Daily (Stock) Chart Reading
Idorsia Ltd. Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Classification
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.07 |
| 52 Week Low | 1.3715 |
| Average Volume | 40,656 |
| 200-Day Moving Average | 3.75 |
| 50-Day Moving Average | 2.01 |
| 20-Day Moving Average | 2.27 |
| 10-Day Moving Average | 2.13 |
| Average True Range | 0.34 |
| RSI (14) | 44.44 |
| ADX | 20.86 |
| +DI | 12.52 |
| -DI | 13.68 |
| Chandelier Exit (Long, 3 ATRs) | 1.82 |
| Chandelier Exit (Short, 3 ATRs) | 2.73 |
| Upper Bollinger Bands | 2.89 |
| Lower Bollinger Band | 1.65 |
| Percent B (%b) | 0.21 |
| BandWidth | 54.40 |
| MACD Line | -0.05 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0829 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.00 | ||||
| Resistance 3 (R3) | 2.01 | 1.99 | 1.98 | ||
| Resistance 2 (R2) | 1.99 | 1.97 | 1.98 | 1.98 | |
| Resistance 1 (R1) | 1.95 | 1.95 | 1.94 | 1.94 | 1.97 |
| Pivot Point | 1.93 | 1.93 | 1.93 | 1.93 | 1.93 |
| Support 1 (S1) | 1.89 | 1.91 | 1.88 | 1.88 | 1.85 |
| Support 2 (S2) | 1.88 | 1.90 | 1.87 | 1.85 | |
| Support 3 (S3) | 1.84 | 1.88 | 1.84 | ||
| Support 4 (S4) | 1.83 |
